Clinical Trial

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)

MOA: Teclistamab is a BCMA x CD3 bispecific antibody.

Key Eligibility Criteria:

• Documented diagnosis of relapsed or refractory multiple myeloma that is measurable
• Subject should have received 1 to 3 prior lines of antimyeloma therapy
  • Minimum of 2 consecutive cycles of an anti-CD38 monoclonal antibody at approved dosing schedule
  • Minimum of 2 consecutive cycles of lenalidomide in any prior line
• ECOG score ≤ 2
• Subjects that received any prior BCMA-directed therapy are excluded
• Subject that received prior pomalidomide therapy and do not meet bortezomib retreatment criteria are not allowed on PCd
• Subjects with prior carfilzomib therapy are not allowed on Kd